ZUG, Switzerland, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of ...

ZUG, Switzerland, SAN JUAN, Puerto Rico and TORONTO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous ...

Aphaia Pharma is a clinical-stage biopharmaceutical company harnessing proprietary precision-targeted drug formulations to restore endogenous hormone release from nutrient-sensing cells in the ...

Aphaia Pharma is a clinical-stage biopharmaceutical company harnessing proprietary precision-targeted drug formulations to restore endogenous hormone release from nutrient-sensing cells in the ...

Aphaia’s lead formulation orchestrates a comprehensive hormonal response from nutrient-sensing cells with potential to modify the course of obesity and associated metabolic diseases. It is currently ...

Aphaia Pharma is a clinical-stage biopharmaceutical company harnessing proprietary precision-targeted drug formulations to restore endogenous hormone release from nutrient-sensing cells in the ...

Swiss/US-based clinical-stage biopharmaceutical company Aphaia Pharma has initiated the dosing of the first subject in a second Phase II trial focused on assessing its oral candidate based on glucose ...

Second Phase 2 trial builds on encouraging initial results from a prior Phase 2 study Aphaia’s formulation activates gastrointestinal nutrient-sensing signaling pathways to modify the course of ...

ZUG, Switzerland and SAN JUAN, Puerto Rico, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company developing precision-targeted drug formulations that harness endogenous ...

ZUG, Switzerland and SAN JUAN, Puerto Rico and TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous ...